Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

| More on:
A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Although Telix Pharmaceuticals Ltd (ASX: TLX) shares have been on fire over the last 12 months, they have recently pulled back.

For example, since peaking at a record high of $19.06 earlier this month, the radiopharmaceuticals company's shares have pulled back by approximately 14% to $16.46.

This hasn't gone unnoticed by analysts at Bell Potter. So much so, the broker believes that investors should be taking advantage of this weakness to snap up the company's shares.

What is the broker saying about Telix Pharmaceuticals shares?

According to the note, the broker has upgraded the company's shares to a buy rating with a $19.00 price target.

Based on where Telix Pharmaceuticals shares currently trade, this implies potential upside of 15.5% for investors over the next 12 months.

Bell Potter believes the pullback is related to its plan to raise funds through a Nasdaq IPO, which is currently taking place. But it feels that smart investors will see this as an opportunity to pick up shares before some potentially positive news is released. It said:

Following the launch of the offer in early June, the stock is trading 14% below its recent high ($19.06) which is likely to be at least in part attributable to an overhang from the raise. The pullback represents an opportunity to buy the stock ahead of an exciting period of news flow over the second half of the CY24 which will include potential FDA approvals for Zircaix and Pixclara.

Clinical programs

The broker highlights that the company is making significant progress with its clinical programs and the funds raised from the Nasdaq listing will accelerate this. It commented:

The clinical trial risk associated with the readout of ProstACT Select is now behind the company. Commencement of enrolment in ProstACT Global in the US is expected to commence next quarter and this will be one of several clinical programs in prostate cancer across both therapy and imaging. The company will also move forward with the development of TLX592 (being its alpha emitter).

It also notes that STARLITE II data is expected in the coming months. It adds:

In renal cancer, the company is expected to readout data from STARLITE II in 2H24. Subject to these results, the renal cancer therapy program will become the third therapeutic candidate behind TLX591 (prostate) and TLX101 (Gliioblastoma). As each of these programs begins to readout data in the coming periods, there is a very significant potential for further value accretion. We highlight this potential with a brief summary of recent transactions in the space, noting that the therapies drive these transactions rather than imaging assets.

All in all, Bell Potter appears to believe these are promising times for Telix Pharmaceuticals shares and its shareholders.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »